DiagnoCure Prods Commercial Partner Hologic to Step Up Marketing for PCA3 Test or Give it Back | GenomeWeb

Unhappy with the sales of its urine-based molecular test for the prostate cancer biomarker PCA3, Canadian cancer diagnostics firm DiagnoCure is urging Hologic, the test's commercial conduit, to either step up commercialization efforts or relinquish rights to the test back to DiagnoCure.

Hologic could accomplish the former option, according to DiagnoCure, by increasing marketing efforts for the assay and porting it from an outdated instrument platform to Hologic's next-generation Panther molecular testing platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.